Journal
PEDIATRIC BLOOD & CANCER
Volume 44, Issue 5, Pages 511-515Publisher
WILEY
DOI: 10.1002/pbc.20249
Keywords
childhood; dermatofibrosarcoma; imatinib; mesylate; protuberans
Categories
Ask authors/readers for more resources
To document the clinical activity of imatinib mesyalte in a child with a dermatofibrosarcoma protuberans (DFSP). An 18-month-old girl presented with a large extremity DFSP. As surgical resection would have caused unacceptable functional defects, imatinib mesylate was administered to induce tumor reduction and or stabilization. After 23 weeks of therapy, magnetic resonance imaging(MRI) of the tumor showed a reduction in the, subcutaneous thickness in the transvers plane. The drug was tolerated well without any adverse reactions. Imatinib mesylate offers a non-surgical alternative for the treatment of large DFSP in children. (c) 2004 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available